Digital Journal, Market Screener, and other websites report that a COVID-19 vaccine candidate, EuCorVac-19, developed by UB spinoff POP Biotechnologies and South Korean pharmaceutical company EuBiologics has been approved for a phase 3 clinical study in South Korea.